AKT1 and B-cell chronic lymphocytic leukemia: The inhibitor also produced a concentration-dependent reduction of AKT activity in CD40-stimulated CLL cells with 10 μM AZD5363 achieving greater than 50% inhibition (Supplementary Figure 2A and 2B).